| Literature DB >> 24480880 |
Saeko Nakajima1, Akihiko Kitoh1, Gyohei Egawa1, Yohei Natsuaki2, Satoshi Nakamizo1, Catharina Sagita Moniaga1, Atsushi Otsuka1, Tetsuya Honda1, Sho Hanakawa1, Wataru Amano1, Yoichiro Iwakura3, Susumu Nakae4, Masato Kubo5, Yoshiki Miyachi1, Kenji Kabashima6.
Abstract
Atopic dermatitis (AD) is generally regarded as a type 2 helper T (Th2)-mediated inflammatory skin disease. Although the number of IL-17A-producing cells is increased in the peripheral blood and in acute skin lesion of AD patients, the role of IL-17A in the pathogenesis of AD remains unclear. To clarify this issue, we used murine AD models in an IL-17A-deficient condition. In a repeated hapten application-induced AD model, skin inflammation, IL-4 production in the draining lymph nodes (LNs), and hapten-specific IgG1 and IgE induction were suppressed in IL-17A-deficient mice. Vγ4(+) γδ T cells in the skin-draining LNs and Vγ5(-) dermal γδ T cells in the skin were the major sources of IL-17A. Consistently, in flaky-tail (Flg(ft/ft) ma/ma) mice, spontaneous development of AD-like dermatitis and IgE induction were attenuated by IL-17A deficiency. Moreover, Th2 differentiation from naive T cells was promoted in vitro by the addition of IL-17A. Taken together, our results suggest that IL-17A mediates Th2-type immune responses and that IL-17A signal may be a therapeutic target of AD.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24480880 DOI: 10.1038/jid.2014.51
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551